Sanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test
Sanofi has been hit with a $250 million impairment charge after an E. coli vaccine candidate it was developing with Johnson & Johnson failed to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
